These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 32140677)

  • 1. Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer.
    Loosen SH; Breuer A; Tacke F; Kather JN; Gorgulho J; Alizai PH; Bednarsch J; Roeth AA; Lurje G; Schmitz SM; Brozat JF; Paffenholz P; Vucur M; Ritz T; Koch A; Trautwein C; Ulmer TF; Roderburg C; Longerich T; Neumann UP; Luedde T
    JHEP Rep; 2020 Apr; 2(2):100080. PubMed ID: 32140677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases.
    Loosen SH; Tacke F; Binnebosel M; Leyh C; Vucur M; Heitkamp F; Schoening W; Ulmer TF; Alizai PH; Trautwein C; Koch A; Longerich T; Roderburg C; Neumann UP; Luedde T
    Oncotarget; 2018 Jun; 9(43):27027-27038. PubMed ID: 29930748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma.
    Loosen SH; Tacke F; Püthe N; Binneboesel M; Wiltberger G; Alizai PH; Kather JN; Paffenholz P; Ritz T; Koch A; Bergmann F; Trautwein C; Longerich T; Roderburg C; Neumann UP; Luedde T
    Carcinogenesis; 2019 Aug; 40(8):947-955. PubMed ID: 30805627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated Serum Levels of CCL23 Are Associated with Poor Outcome after Resection of Biliary Tract Cancer.
    Roderburg C; Labuhn S; Bednarsch J; Lang SA; Schneider AT; Hammerich L; Vucur M; Ulmer TF; Neumann UP; Luedde T; Loosen SH
    Mediators Inflamm; 2022; 2022():6195004. PubMed ID: 36505756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Golgi Protein 73 (GP73) Serum Levels Predict Outcome after Resection of Biliary Tract Cancer.
    Loosen SH; Halpaap J; Labuhn S; Bednarsch J; Alizai PH; Roeth AA; Lang SA; Vucur M; Kather JN; Knoefel WT; Ulmer TF; Neumann UP; Roderburg C; Luedde T
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Levels of CXCL13 Are an Independent Predictor of Survival Following Resection of Biliary Tract Cancer.
    Loosen SH; Ulmer TF; Labuhn S; Bednarsch J; Lang SA; Alizai PH; Schneider AT; Vucur M; Neumann UP; Luedde T; Roderburg C
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy.
    Loosen SH; Gorgulho J; Jördens MS; Schulze-Hagen M; Beier F; Vucur M; Schneider AT; Koppe C; Mertens A; Kather JN; Tacke F; Keitel V; Brümmendorf TH; Roderburg C; Luedde T
    Front Oncol; 2021; 11():646883. PubMed ID: 33869041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Soluble Urokinase Plasminogen Activator Receptor as a Predictive Indicator for COVID-19-Associated Acute Kidney Injury and Mortality: Clinical and Bioinformatics Analysis.
    Abdellatif HAA; Sultan BO; Nassar HM; Gomaa MEE; Sakr MG; Riad E; Al-Harbi AI; Abdulhakim JA; Fawzy MS; Abd El-Fadeal NM
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis.
    Özdirik B; Maibier M; Scherf M; Nicklaus JM; Frohme J; Puengel T; Meyer Zum Büschenfelde D; Tacke F; Mueller T; Sigal M
    J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPS.
    Loosen SH; Benz F; Mohr R; Reuken PA; Wirtz TH; Junker L; Jansen C; Meyer C; Praktiknjo M; Wree A; Reißing J; Demir M; Gu W; Vucur M; Schierwagen R; Stallmach A; Kunstein A; Bode J; Trautwein C; Tacke F; Luedde T; Bruns T; Trebicka J; Roderburg C
    JHEP Rep; 2024 May; 6(5):101054. PubMed ID: 38681861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis.
    Loosen SH; Schulze-Hagen M; Vucur M; Gorgulho J; Paffenholz P; Benz F; Mohr R; Demir M; Wree A; Kuhl C; Trautwein C; Tacke F; Bruners P; Luedde T; Roderburg C
    JGH Open; 2021 Mar; 5(3):356-363. PubMed ID: 33732882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure.
    Koch A; Zimmermann HW; Gassler N; Jochum C; Weiskirchen R; Bruensing J; Buendgens L; Dückers H; Bruns T; Gerken G; Neumann UP; Adams DH; Trautwein C; Canbay A; Tacke F
    Liver Int; 2014 Oct; 34(9):1330-9. PubMed ID: 24575897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
    Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
    Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble urokinase plasminogen activator receptor (suPAR) in children with obesity or type 1 diabetes as a marker of endothelial dysfunction: a cross-sectional study.
    Kostopoulou E; Kalavrizioti D; Davoulou P; Sinopidis X; Papachristou E; Goumenos DS; Dimitriou G; Spiliotis BE; Papasotiriou M
    Eur J Pediatr; 2024 May; 183(5):2383-2389. PubMed ID: 38448612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
    Stephens RW; Nielsen HJ; Christensen IJ; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
    J Natl Cancer Inst; 1999 May; 91(10):869-74. PubMed ID: 10340907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Predictive Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention.
    Qin Y; Qiao Y; Wang D; Yan G; Tang C; Ma G
    Int J Gen Med; 2021; 14():6497-6504. PubMed ID: 34675617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma.
    Roderburg C; Loosen SH; Bednarsch J; Alizai PH; Roeth AA; Schmitz SM; Vucur M; Luedde M; Paffenholz P; Tacke F; Trautwein C; Ulmer TF; Neumann UP; Luedde T
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality.
    Zimmermann HW; Reuken PA; Koch A; Bartneck M; Adams DH; Trautwein C; Stallmach A; Tacke F; Bruns T
    J Intern Med; 2013 Jul; 274(1):86-100. PubMed ID: 23432143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.